Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma

Journal of Investigative Dermatology

Volumn 133, Issue 5, 2013, Pages 1278-1285

  Nigro, Cristiana Lo ^a   Wang, Hexiao ^b   McHugh, Angela ^b   Lattanzio, Laura ^a   Matin, Rubeta ^c   Harwood, Catherine ^c   Syed, Nelofer ^d   Hatzimichael, Eleftheria ^e   Briasoulis, Evangelos ^e   Merlano, Marco ^a   Evans, Alan ^f   Thompson, Alastair ^b   Leigh, Irene ^b   Fleming, Colin ^b   Inman, Gareth J ^b   Proby, Charlotte ^b   Crook, Tim ^b  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF IOANNINA   (Greece)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GENOMIC DNA; PLACENTA PROTEIN 5;

ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTATIC MELANOMA; PIGMENTED NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84876670279     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.493     Document Type: Article

References (21)

1. Ascierto PA, Simeone E, Giannarelli D et al. (2012) Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 10:107
2. Beasley GM, Parsons C, Broadwater G et al. (2012) A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg 256:350-6
3. Bretz N, Noske A, Keller S et al. (2012) CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-depen-dent fashion. Clin Exp Metastasis 29:27-38
4. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
5. Chin L (2003) The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 3:559-70
6. Flaherty KT (2011) Next generation therapies change the landscape in melanoma. F1000 Med Reports 3:8
7. Flaherty KT (2012) Targeting metastatic melanoma. Annu Rev Med 63:171-83
8. Flaherty KT, Robert C, Hersey P et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-14
9. Gessler F, Voss V, Seifert V et al. (2011) Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci Lett 497:49-54
10. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-7
11. Hanaizi Z, Van Zwieten-Boot B, Calvo G et al. (2012) The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 48:237-42
12. Hibi K, Goto T, Shirahata A et al. (2011) Detection of TFPI2 methylation in the serum of gastric cancer patients. Anticancer Res 31:3835-8
13. Hibi K, Goto T, Shirahata A et al. (2012) Methylation of TFPI2 no longer detected in the serum DNA of colorectal cancer patients after curative surgery. Anticancer Res 32:787-90
14. Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13:484-92
15. Kempaiah P, Kisiel W (2008) Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human fibrosarcoma cell line. Apoptosis 13:702-15
16. Liu S, Ren S, Howell P et al. (2008) Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 21:545-58
17. Lopez J, Percharde M, Coley HM et al. (2009) The context and potential of epigenetics in oncology. Br J Cancer 100:571-7
18. Nobeyama Y, Okochi-Takada E, Furuta J et al. (2007) Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. International journal of cancer. J Int du Cancer 121:301-7
19. Oonk MH, Eijsink JJ, Volders HH et al. (2012) Identification of inguinofemoral lymph node metastases by methylation markers in vulvar cancer. Gynecol Oncol 125:352-7
20. Orcurto V, Denys A, Voelter V et al. (2012) (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study. Melanoma Res 22:63-9
21. Robertson KD, Wolffe AP (2000) DNA methylation in health and disease. Nat Rev Genet 1:11-9